A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 2, 2005, Pages 124-129

  Mace, Shubhra ^a   Taylor, David ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotic agents; Polypharmacy; Prescription

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; CONTROLLED STUDY; DRUG MEGADOSE; ETHNOLOGY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; MENTAL PATIENT; PHARMACIST; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PUBLICATION; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 21044438452     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510028995     Document Type: Review

References (20)

1. National Institute for Clinical Excellence, Technology appraisal 43, Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia, June 2002.
2. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6.
3. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10 year prospective study. Br J Psychiatry 1998;173:325-9.
4. Edwards S, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984;145:502-7.
5. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987;150: 501-4.
6. Harrington M, Lelliott P, Paton C, et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002;26:414-8.
7. Taylor DM. Prescribing of clozapine and olanzapine: Dosage, polypharmacy and patient ethnicity. Psychiatr Bull 2004;28:241-3.
8. Taylor D, Mace S, Mir S. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000;4: 41-6.
9. Yorston G, Pinney A. The use of high-dose antipsychotic medication. Psychiatr Bull 1997;21:566-9.
10. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73.
11. Taylor D. Switching from typical to atypical antipsychotics: Practical guidelines. CNS Drugs 1997;8(4):285-92.
12. Lelliott P, Paton C, Harrington M, et al. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 2002;26:411-4.
13. Kreyenbuhl J, Zito J, Buchanan R, et al. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003;29(2):183-93.
14. Diaz F, De Leon J. Excessive antipsychotic dosing in 2 U.S. state hospitals. J Clin Psychiatry 2002;63:998-1003.
15. Walkup J, McAlpine D, Olfson M, et al. Patients with Schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61:344-8.
16. Segal S, Bola J, Watson M. Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Services 1996;47:282-6.
17. Jann M, Chang W, Lam Y, et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog Neuro-Psychopharmacol Biol Psychiatry 1993;16:93-202.
18. Chang W, Jann M, Hwu H, et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American Non-Chinese. J Formosan Med Assoc 1991;90:572-8.
19. Zhang-Wong J, Beiser M, Zipursky R, et al. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998;81:333-9.
20. Lin K, Poland R, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenia patients. Am J Psychiatry 1989; 146:1307-11.